Brief: Casi Pharmaceuticals Statement On Status Under Holding Foreign Companies Accountable Act
01/04/2022 12:19
April 1 (Reuters) - CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS STATEMENT ON STATUS UNDER HOLDING
FOREIGN
COMPANIES ACCOUNTABLE ACT
* CASI PHARMACEUTICALS-EVALUATING STRATEGIC OPTIONS, WHICH
INCLUDE
BUT NOT LIMITED TO ADDING BUSINESS PROCESSES, CONTROL TO MEET
REQUIREMENTS OF HFCAA
Source text for Eikon: ID:nPncc0DnMa
Further company coverage: CASI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary